Health ❯ Nutrition ❯ Weight Management

Obesity

Weight Loss Medications Lifestyle Changes Weight Loss Drugs Health Risks Drug Treatments Weight-loss Medications Treatment Options GLP-1 Receptor Agonists Visceral Fat GLP-1 Drugs Food Noise Medication Weight-loss Drugs Gastric Band Surgery Dietary Strategies Weight Loss Anti-Obesity Medications Epigenetics Eating Disorders Clinical Trials GLP-1 Medication GLP-1 Medications BMI Criteria BMI Calculation Breast Cancer Health Outcomes Pharmacotherapy Fat-Free Mass Drug Impact on Muscle Menopause Dietary Habits Drug Efficacy Heart Health Weight Loss Treatments Polycystic Ovary Syndrome Body Composition Metabolic Health Cognitive Decline Cholesterol Levels Wegovy Weight-Loss Surgery Weight-Loss Drugs Diet Industry Child Health Health Conditions Semaglutide Fettzellen Reality TV Effects Cardiometabolic Health Impact on Mental Health GLP-1 Hormone Pharmaceutical Treatments Weight Loss Injections BMI Standards Weight Loss Strategies Pharmaceutical Interventions Weight Loss Challenges Public Perception Oral Medications Body Mass Index Yo-Yo Effect Medications for Obesity Weight Gain

Heart Risks Rebound After GLP-1 Breaks, New Data Show Continuous Use Is Safest

A three-year Veterans Affairs analysis ties treatment pauses to higher cardiovascular events.

Oprah Winfrey Recounts Joan Rivers’ 1985 On‑Air Body‑Shaming, Connecting It to a New Health Push

Oprah Winfrey Recasts Obesity as Disease in New Book, Backs GLP-1s as Long-Term Care

Oxford Review Finds GLP-1 Weight Loss Largely Lost Within About Two Years After Stopping

Oprah Credits GLP-1s With Ending Alcohol Cravings, Plans Lifelong Use

Hims & Hers in Talks With Novo Nordisk on Wegovy After Q3 Revenue Beat

Lancet Analysis: Semaglutide Cuts Major Heart Events Regardless of Weight Loss

Weight Swings in Older Adults Linked to Faster Cognitive Decline, Study Finds

Mouse Study Finds Ozempic Reduces Lean Mass and Shrinks Organs

GLP-1 Weight-Loss Drugs Fail to Boost Fitness and Cause Significant Muscle Loss